Pneumococcal Conjugate Vaccine Market 2020-2025 Major Players Hitting the Reset Button for Growth | Pfizer, GSK, Sanofi, Merck, Walvax, Royal (Wuxi) Bio-Pharma, Zhifei Biologic, Serum Institute

Business Industry Reports Research has recently announced a report on Global Pneumococcal Conjugate Vaccine Market based on the Healthcare Industry. The Pneumococcal Conjugate Vaccine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2025.

Global Pneumococcal Conjugate Vaccine Market overview:

Pneumococcal conjugate vaccine is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae. It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children. The Global Pneumococcal Conjugate Vaccine Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273720 .

On the Basis of Product Type segment, the Pneumococcal Conjugate Vaccine Market is sub segmented into 23-valent Vaccine, 10-valent Vaccine, 7-valent Vaccine and 13-valent Vaccine. Based on End Use Industry segment, the Pneumococcal Conjugate Vaccine Market is segmented as Child and Adult.

There are several manufacturers of Pneumococcal Conjugate Vaccine in Europe and North America. In North America, the demand for Pneumococcal Conjugate Vaccine is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Pneumococcal Conjugate Vaccine Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273720/single .

Top Industry News:

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR PFIZER’S XALKORI (CRIZOTINIB) FOR THE TREATMENT OF PEDIATRIC ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA on 23 September, 2020 -- Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. XALKORI received Breakthrough Therapy designation (BTD) for the ALK-positive ALCL indication in May 2018 and if approved, would be the first biomarker-driven therapy for this type of pediatric lymphoma. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is January 2021.

“Despite high survival rates for children with ALK-positive anaplastic large cell lymphoma, many will relapse, requiring novel treatment approaches,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “Today’s FDA filing exemplifies Pfizer’s commitment to broadening the use of biomarker-driven therapies in areas with significant needs, such as rare, pediatric cancers. Given XALKORI’s proven efficacy in ALK-positive lung cancer and activity seen in clinical trials investigating relapsed or refractory ALK- and ROS-1 positive anaplastic large cell lymphoma, if approved, XALKORI could represent an important step toward improving outcomes for children with this type of cancer.”

Anaplastic large cell lymphoma is a rare type of non-Hodgkin lymphoma (NHL), divided into ALK-positive or ALK-negative disease. Though the five-year survival rate for children with cancer in the U.S. is now the highest it’s ever been at 80%, children with cancer continue to face challenges in treating their disease, including rare tumor types, variations in medicine response and prolonged risk of side effects.

“Children with cancer and their families have been desperate for new and innovative medicines. We applaud Pfizer’s commitment to drug discovery and development to help address childhood cancers, and continue to work together on behalf of patients with these cancers,” said George Dahlman, Chief Executive Officer, Children’s Cancer Cause. “We look forward to potentially having a new biomarker-driven therapy for children with relapsed or refractory ALK-positive ALCL that may help improve these children’s lives.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273720 .

Major Key Players:

Some of the Pneumococcal Conjugate Vaccine Market manufacturers involved in the market are Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biologic, Serum Institute of India in World, effective mergers are some of the strategies adopted by the Pneumococcal Conjugate Vaccine Market manufacturers. New product launches and continuous technological innovations are the Pneumococcal Conjugate Vaccine Market strategies adopted by the major players.

Table of Contents:

1 Pneumococcal Conjugate Vaccine(PCV) Product Definition
2 Global Pneumococcal Conjugate Vaccine(PCV) Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Pneumococcal Conjugate Vaccine(PCV) Shipments
2.2 Global Manufacturer Pneumococcal Conjugate Vaccine(PCV) Business Revenue
2.3 Global Pneumococcal Conjugate Vaccine(PCV) Market Overview
3 Manufacturer Pneumococcal Conjugate Vaccine(PCV) Business Introduction
3.1 PFIZER Pneumococcal Conjugate Vaccine(PCV) Business Introduction
3.1.1 PFIZER Pneumococcal Conjugate Vaccine(PCV) Shipments, Price, Revenue and Gross profit 2020-2025
3.1.2 PFIZER Pneumococcal Conjugate Vaccine(PCV) Business Distribution by Region
3.1.3 PFIZER Interview Record
3.1.4 PFIZER Pneumococcal Conjugate Vaccine(PCV) Business Profile
3.1.5 PFIZER Pneumococcal Conjugate Vaccine(PCV) Product Specification
3.2 GSK Pneumococcal Conjugate Vaccine(PCV) Business Introduction
3.2.1 GSK Pneumococcal Conjugate Vaccine(PCV) Shipments, Price, Revenue and Gross profit 2020-2025
3.2.2 GSK Pneumococcal Conjugate Vaccine(PCV) Business Distribution by Region
3.2.3 Interview Record
3.2.4 GSK Pneumococcal Conjugate Vaccine(PCV) Business Overview
3.2.5 GSK Pneumococcal Conjugate Vaccine(PCV) Product Specification
3.3 SANOFI Pneumococcal Conjugate Vaccine(PCV) Business Introduction
3.3.1 SANOFI Pneumococcal Conjugate Vaccine(PCV) Shipments, Price, Revenue and Gross profit 2020-2025
3.3.2 SANOFI Pneumococcal Conjugate Vaccine(PCV) Business Distribution by Region
3.3.3 Interview Record
3.3.4 SANOFI Pneumococcal Conjugate Vaccine(PCV) Business Overview
3.3.5 SANOFI Pneumococcal Conjugate Vaccine(PCV) Product Specification
3.4 Merck Pneumococcal Conjugate Vaccine(PCV) Business Introduction
3.5 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine(PCV) Business Introduction
3.6 Zhifei Biologic Pneumococcal Conjugate Vaccine(PCV) Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.